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A pharmacokinetic program that allows individualization of drug dosage regimens through the Bayesian method is 
described. The program, which is designed for the Hewlett-Packard HP-41 CV calculator, is based upon the 
one-compartment open model with either instantaneous or zero-order absorption. Individualized estimation of the 
patient's kinetic parameters (clearance and volume of distribution) is performed by analyzing the plasma levels 
measured in the patient as well as considering the population data of the drug. After estimating the individual kinetic 
parameters by the Bayesian method, the program predicts the dosage regimen that will elicit the desired peak and 
trough plasma levels at' steady state. For comparison purposes, the least-squares estimates for clearance and volume of 
distribution are calculated, and dosage prediction can also be made on the basis of the least-squares estimates. The 
least-squares estimates can be used to calculate population pharmacokinetic parameters according to the Standard 
Two-Stage method. 
Several examples of clinical use of the program are presented. The examples refer to patients with classic hemophilia 
who were treated with Factor VIII concentrates. In these patients, the Bayesian kinetic parameters of Factor VIII have 
been estimated through the calculator program. The Bayesian parameter estimates generated by the HP-41 have been 
compared with those determined by a Bayesian program (ADVISE) designed for microcomputers. 
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1. INTRODUCTION 
The Bayesian me thod  [1,2] is a relat ively recent  
technique for p red ic t ing  p l a sma  drug levels and  
ind iv idua l iz ing  dosage  regimens.  This technique  
has  an impor t an t  advan tage  in that  it exploi ts  the 
in fo rma t ion  resul t ing f rom the p l a sma  levels which 
have been measured  in the pa t ien t  concerned,  as 
well as in fo rma t ion  abou t  the kinet ic  response  to 
the drug  observed  in pa t i en t  popu la t ions  previ-  
ously  t rea ted  with the drug. Thus,  the ma in  fea ture  
of  the Bayesian me thod  is that  bo th  ind iv idua l  and  
* To whom all correspondence should be sent. 
popu l a t i on  kinet ic  da ta  con t r ibu te  to the es t ima-  
t ion of the best-f i t  k inet ic  pa ramete r s  for a given 
pat ient .  Conversely ,  the o lder  kinet ic  techniques 
for  indiv idual iz ing  the dosage  regimen of  drugs 
[3-7]  were only  based  upon  the p l a sma  levels 
measured  in the pat ient .  
The  Bayesian me thod  can be app l i ed  in cl inical  
prac t ice  by  using a number  of compu te r  p rog rams  
[8-12].  A m o n g  these, the A D V I S E  p r o g r a m  [12], 
des igned for  the Hewle t t -Packa rd  H P - 8 5 / 8 7  mi-  
c rocompute r ,  is one  of the most  c o m m o n l y  used. 
Dur ing  the pas t  five years,  low-cost  hand-he ld  
ca lcula tors  have been  widely  used for pha rmaco -  
k inet ic  app l i ca t ions  [13-24].  The  Hewle t t -Packa rd  
0010-468X/85/$03.30 © 1985 Elsevier Science Publishers B.V. (Biomedical Division) 
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HP-41 model is the hand-held calculator for which 
the largest number of programs have been pub- 
fished [16-24]. In fight of the growing interest of 
clinicians in using hand-held calculators for 
pharmacokinetics, we have developed an HP-41 
calculator program that allows for clinical use of 
the Bayesian method. 
Although our HP-41 program employs the fin- 
earized Bayesian method in its simplest imple- 
mentation for the one-compartment model, this 
calculator program performs essentially the same 
functions as the original HP-85/87 computer pro- 
gram. The data of 12 hemophiliacs treated with 
Factor VIII concentrates have been used to dem- 
onstrate the clinical application of the HP-41 
Bayesian program. Finally, in Appendix 3 it is 
shown that the program can also be used to obtain 
population pharmacokinetic parameters according 
to the Standard Two-Stage method. 
2. THEORY 
Our HP-41 program is based on the one-com- 
partment kinetic model with instantaneous ab- 
sorption. The equation for such model is the fol- 
lowing: 
D - (CL/Vd) t  Cp = --v-~ e (1) 
where: 
Cp is the plasma level at the time t; 
t is the time elapsed after the dose; 
CL is the clearance; 
D is the administered dose; 
Vd is the apparent volume of distribution. 
When repeated doses are given, the time-course of 
plasma levels can be calculated by application of 
the superposition principle [25]. 
As shown in Appendix 1, our program is desig- 
ned in such a way that the user may select the 
one-compartment model with zero-order input 
when necessary. The selection of the latter model 
is needed in those cases (e.g. administration of the 
drug by oral route or by constant-rate intravenous 
infusion) where the drug absorption cannot be 
assumed to be instantaneous. 
The current presentation of our procedure is 
focused on the application of the Bayesian method 
to the kinetics of Factor VIII. Since the one-com- 
partment model with instantaneous absorption is 
appropriate for Factor VIII [26], only the use of 
the one-compartment model with zero-order input 
is discussed in Appendix 1. 
Before presenting our simplified Bayesian pro- 
cedure, the original Bayesian feedback method, as 
implemented by Sheiner in the ADVISE computer 
program [12], will be briefly described. 
2.1. The theoretical basis of the ADVISE program 
Given a set of n plasma concentrations mea- 
sured in a patient, the Bayesian feedback method 
performs estimation of the best-fit values of the 
one-compartment kinetic variables (namely CL 
and Vd). Such estimation can be performed with 
regard to any dosage regimen and any combina- 
tion of plasma samplings. The Bayesian method 
determines the best-fit parameter estimates by 
using population and individual kinetic data. The 
population average values of the kinetic parame- 
ters must therefore be known, along with their 
interindividual standard deviations. The value of 
the residual intraindividual and model misspecifi- 
cation error variability, as previously defined 
[27,28], must be known as well. The HP-85/87 
Bayesian procedure performs estimation of the 
one-compartment kinetic parameters from the 
plasma level data by using a simple algorithm. In 
such estimation, the ADVISE program can model 
the absorption process either as an instantaneous 
or as a zero-order process; under the latter cir- 
cumstance, the user must provide an estimate of 
the period (T) over which the zero-order absorp- 
tion occurs since the computer program is unable 
to calculate an estimate of this parameter. 
2.2. The theoretical basis of the HP-41 program 
The program input consists of the following 
data: 
Administered doses (Dj) and times (tnj) at which 
the doses were given. 
Measured plasma concentrations (Ci) and times 
(tci) at which the concentrations were measured. 
Population average values for CL and Vd(CLpo p 
and Vpo p) and respective standard deviations (SDcL 
and SDv). 
Coefficient of variation for residual error (CVRE); 
the residual error (RE) refers to the intraindividual 
and model misspecification error variability. 
All time values are entered as date and hour: 
the day on which the first dose was given is 
arbitrarily designated as 'day 1'; the code for all 
subsequent days is defined accordingly. 
In the framework of the Bayesian theory, our 
HP-41 program employs a linear approximation 
method to calculate the best-fit estimates of CL 
and lid from the measured plasma levels. This 
method proceeds by the following steps: 
(a) Initialize: set CL and Vd to population aver- 
age values and CVRE to the population value 
of the coefficient of variation for RE. Also 
set: i = 0, wll = SDZv, w2z -- SD2L and w12 = 0. 
(b) Store: all values of Dj and toj in program 
memory. 
(c) Set: i = i +  l 
(d) Input: the C, value to be used for feedback 
adjustment of CL and Vd; if none, exit. 
(e) Compute: 
C/i= ~ Ds ' exp ( - [CL /Vd][ t c i - t oJ ] )  
Vd j = l  
where C/, is the fitted value of concentration 
and r is the number of dose values for which 
tDj is less than tcv 
( f ) Compute: 
Cv, = ~ ( ( D j ' e x p ( - [ C L / V d l [ t c i - t n j ] ) )  
j ~ l  
× (CL[ t c i -  tDj ] -- Vd) / l ' d  s } 
Ccc, = ~ { ( D j ' e x p ( - [ C L / V d ] [ t c i - t o j ] ) )  
j ~ l  
E i = C i - C f i  
where cv, and CcL ~ are the partial derivatives 
of Cp with respect to Vd and CL, respectively. 
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(g) Compute: 
d = w 1~w22 - wlZ2 
= ev , / (CVREC,)  W~ 1 w22/d + 2 2 
w~2 = - w n / d  + Cv, CcL,/( CVREC,)2 
w~2 = w , , / d  + e~L,I( C VRE C, )2 
( h ) Compute: 
d* = wt, w~ - w~d 
g~, = w72/ d* 
g ~  = - w ~ / d *  
g ~  = W7l/d* 
(i) Estimate: 
va* = va + g,~cv, e , / (  CVREC,)2 
+ g,2Cc~,E,/( CVREC,)2 
CL* = CL + g12CviEJ(CVREC,) 2 
+ g~2Cc~,E,/(CVR~C,)2 
where Vd* and CL* are the values of lid and 
CL after the feedback adjustment. 
( j )  Set: 
Vd = Vd*; CL = CL* 
Wll = gll ; w12 ~-- g12; w22 = g22 
(k) Return to step (c). 
It can be seen that the above algorithm is very 
similar to that proposed by Vozeh et al. for calcu- 
lating phenytoin kinetic parameters through the 
Bayesian method [27]. 
The HP-41 calculator program that we have 
developed implements the algorithm described 
above. The program is described in detail in Ap- 
pendix 2. 
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After calculating the Bayesian estimates for CL 
and Vd from the plasma level data, for compari- 
son purposes the program also determines the 
least-squares estimates for these two parameters. A 
weighted iterative least-squares procedure (the 
Gauss-Newton algorithm) is employed to perform 
the latter function (concentration values are 
weighted according to 1/C2) .  
Finally, the program is able to compute the 
dosage regimen (maintenance dose and dosing in- 
terval) capable of eliciting the desired maximum 
and minimum plasma concentrations at steady 
state. The calculation is performed by using the 
equations described by Ng [29]. Moreover, the 
program adopts the same 'practical '  dosing inter- 
vals reported by Ng. 
To demonstrate the clinical application of the 
HP-41 program, some examples concerning the 
kinetics of Factor VIII are presented below. 
3. EXAMPLES OF CLINICAL APPLICATION 
OF THE PROGRAM:  INDIVIDUALIZA-  
TION OF FACTOR VIII  DOSAGE IN PA- 
TIENTS WITH CLASSIC HEMOPHILIA 
The need to individualize the dosage of Factor 
VIII  in hemophiliacs has been addressed in recent 
studies [23,30]. Such individualization is useful 
particularly when a patient is to be treated with a 
multiple-dose therapy with Factor VIII. 
We obtained the population parameters for 
/ 
TABLE 1 
Population kinetic parameters for a Factor VIII concentrate a 
Parameter Unit Value 
CLpo p ml/h/kg 4.42 
SDcL ml/h/kg 1.81 
Vpo p ml/kg 56.3 
SD v ml/kg 17.1 
CVRE Dimensionless 0.21 
a The parameters have been estimated retrospectively from the 
kinetic data of a patient population of 27 hemophiliacs 
(mean age 29.3 years), for whom 179 data points were 
available. The Standard Two-Stage method described in Ap- 
pendix 3 was used to determine these parameters. 
TABLE 2 
Comparison between the Bayesian parameter estimates gener- 
ated by the HP-41 and the HP-85/87 programs 
Patient Bayesian estimates 
code a HP-41 program HP-85/87 program 
CL Vd CL Vd 
(ml/kg/h) (ml/kg) (ml/kg/h) (ml/kg) 
1 3.41 48.6 3.47 48.2 
2 1.77 58.8 2.15 52.1 
3 4.17 56.4 4.16 56.3 
4 4.24 50.2 4.22 50.0 
5 4.77 59.4 4.79 59.5 
6 2.27 41.2 2.55 35.4 
7 4.23 54.6 4.22 54.5 
8 6.68 71.0 7.08 71.0 
9 3.89 58.4 3.88 57.8 
10 4.28 55.4 4.28 55.4 
11 3.91 49.4 3.91 49.2 
12 3.16 51.2 3.26 50.2 
a Patient's data are given in detail in a previous report [30]. 
Factor VIII from the data of 27 hemophiliacs 
treated with a Factor VIII concentrate (Kryobulin- 
Immuno) at the Hemophilia Center of the Careggi 
Hospital (Florence) from January 1982 to June 
1984. The Standard Two-Stage method was em- 
ployed to calculate the population parameters (see 
Appendix 3). The population mean values for CL 
and Vd are presented in Table 1, along with their 
standard deviations and the value of CVRE. 
To assess the agreement between the parameter 
estimates generated by the HP-41 and the HP- 
85/87 programs, we retrospectively analyzed the 
previously published kinetic data of 12 hemo- 
philiacs treated with Factor VIII [30]. In these 
patients, a limited number of plasma samples were 
drawn after a test dose in an attempt to char- 
acterize the kinetic behavior of Factor VIII on the 
basis of the test-dose kinetic data. All patients 
received a multiple-dose treatment with Factor 
VIII; the dosage regimen was determined by using 
the Sawchuk-Zaske method [30]. 
In the present analysis, two plasma levels drawn 
approximately 3 and 9 h after the initial dose were 
analyzed in each patient and the Bayesian esti- 
mates for CL and Vd were determined from these 
two plasma levels. For this purpose, both the 
HP-41 and HP-85/87 programs were used in order 
to compare the parameter estimates generated by 
the two programs. The results of this analysis are 
given in Table 2. It can be seen that the Bayesian 
parameters estimated by the HP-41 program are 
consistent with those estimated by the ADVISE 
program. The data reported in Table 2 were 
evaluated by linear regression analysis (the HP-41 
parameters were regressed on the HP-85/87 
parameters). The following results were obtained: 
Clearance: regression line CLHP_41 = - 0.092 + 
0.998 CL HP-SS; correlation coefficient = 0.992. 
Apparent volume of distribution: regression line 
VdHP.41 = 9.257 + 0.850 VdHP_85; correlation coef- 
ficient = 0.963. 
To better illustrate the clinical use of the HP-41 
program, the data of Patient 8 are presented in 
detail. This patient (age 30 years, weight 61 kg, 
baseline Factor VIII  plasma concentration 0.0088 
units/ml)  received 1 000 units of Factor VIII  (test 
dose) for a minor bleeding episode. Two plasma 
samples were taken after the test dose (Table 3). 
Before inputting the plasma level data into the 
calculator program, the kinetic correction for the 
endogenous synthesis of Factor VIII [26] was per- 
formed. Therefore, the baseline Factor VIII plasma 
level was subtracted from the two measured con- 
centrations. The two time-concentration data 
points were then analyzed using the HP-41 pro- 
gram. Fig. 1 shows the printed output provided by 
the calculator. 
Another example of clinical application of the 
program is presented in Fig. 2. This example refers 
to a hemophilia patient (age 28 years, weight 58 
kg) who received three Factor VIII  doses 
(Kryobulin-Immuno) prior to application of the 
TABLE 3 
Administered dose and measured plasma Factor VIII levels for 
Patient 8 a 
Hour Dose Level 
(units/kg) (units/ml) 
9:00 a.m. 16.4 
11:45 a.m. 0.1589 
7:30 p.m. 0.0842 
a The patient was treated with Kryobulin-Immuno. 
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Fig. 1. This figure describes application of the HP-41 program 
to the kinetic data of Patient 8. The administered dose and the 
measured concentrations of Factor VIII are shown on the left 
of the figure; on the right, the calculated parameter estimates 
and the suggested dosage regimen (12.2951 units/kg, corre- 
sponding to 750 units, every 12 h) are reported. The symbols 
appearing in this figure are explained in Table 4. The half-life 
(T1/2) is calculated as 0.693 Vd/CL. 
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Bayesian program. Three previous plasma levels of 
Factor VIII were available for this patient. Since 
the patient had a baseline Factor VIII level close 
INIT. NEW POP ESTIM? 
NO 
INST. ABSOR. ? 
YES CV RE=@.2188 
MEAN Vd=56.3088 
ENTER DflT~ SDEV Vd=17.1@@@ 
MEAN CL=4.4280 
DAY I SDEV CL=I.81@B 
N=9.@~ PARAMETER 
D=17.2e@@ ESTIMATION 














DAY 2 PEflK TIME=@.25@@ 
DES. NAX=0.3@@@ 
H:17.88 DES, MIN=O.I@88 
C=8,1888 RND=4,31@@ 
DAY 3 LD=21.5580 
MD=12.93$@ 
14= 17.0~ PEAK T I ME=e. 2580 
C=e. 8820 TAU= 12, 8098 
PRED. MAX=8.3167 
PRED. MIN=@, 1291 
NEW PRED. 
NO 
Fig. 2. In this example, the HP-41 program is used to analyze 
the data of a hemophilia patient with a more complex dosing 
history. The optimal dosage regimen is determined based on 
the Bayesian estimates of CL and Vd. 
to zero, the kinetic correction for the endogenous 
synthesis of Factor VIII [26] was not employed. As 
shown in Fig. 2, the HP-41 program was used to 
calculate the values of CL and I'd through the 
Bayesian and least-squares methods. The optimal 
dosage regimen for the patient was then de- 
termined using the Bayesian estimates of CL and 
I'd. 
4. DISCUSSION 
Over the past few years Bayesian analysis has 
increasingly been used for individualizing drug 
dosage regimens. Unfortunately, the previously 
published programs for applying the approach in 
clinical practice were generally designed for micro- 
computers. Although these computers have several 
important advantages over hand-held calculators 
in terms of graphics capabilities, storage capacity, 
and the ability to generate formatted consult re- 
ports for inclusion in the patient's medical records, 
programmable calculators are generally more 
widely available in many institutions. Thus, the 
HP-41 program described herein may be of value 
for routine use. 
In order to demonstrate the accuracy of this 
program we have shown that the parameter esti- 
mates obtained with the HP-41 program are very 
similar to the results obtained using the original 
ADVISE program. We are currently in the process 
of assessing the prospective predictive ability of 
this program to determine Factor VIII mainte- 
nance dosing requirements from data available 
following a test dose. Preliminary results in this 
area are encouraging. 
It is important to note that, although the exam- 
ples presented herein refer to the kinetics of Factor 
VIII, this program has general applicability and 
can be applied to any drug for which the one-com- 
partment model is appropriate (e.g. theophylline 
and the aminoglycosides). 
Finally, it should be stressed that the theoretical 
basis of the HP-41 program is slightly different 
from that implemented in the ADVISE program. 
In the present report, a limited amount of data is 
given concerning the relative performance of the 
HP-41 and HP-85/87 programs. Further studies 
are needed, however, to more fully evaluate the 
HP-41 program. 
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APPENDIX 1: BAYESIAN ESTIMATION OF 
TH E  PARAMETERS OF THE ONE-COM- 
PARTMENT MODEL WITH ZERO-ORDER 
ABSORPTION 
A function of the HP-41 program allows the 
user to select the one-compartment model with 
zero-order input when necessary. Use of such a 
kinetic model is needed when the drug is adminis- 
tered by constant rate intravenous infusion or by 
the oral route. 
The one-compartment model with zero-order 
input is based on the following equation: 
D .  e x p ( - [ C L / V d ] [ t  - PT ]) 
c p  = C L  . I " T  
× (1 - e x p ( - [ C L / V a ] [ e r ] ) )  
where t is the time elapsed since the start of the 
intravenous infusion or, in the case of the oral 
route, the time elapsed since oral dosing; and PT 
is the duration of the constant rate intravenous 
infusion or, in the case of the oral route, the period 
over which absorption occurs (peak time). 
From the above equation it appears that, if one 
has to use the program for drugs administered by 
the oral route, the drug absorption must be as- 
sumed to be a zero-order process. This is a rea- 
sonable approximation for many drugs and should 
not introduce expressive error. 
In the HP-41 program, the Bayesian estimation 
of CL and Vd on the basis of the above model is 
performed by using the algorithm described in 
Section 2.2 for the one-compartment model with 
instantaneous absorption. The only differences are 
the following: at steps (e)  and ( f ) ,  the values of 
C/. Cvi, and CCL i a r e  calculated according to 
equations: 
C/i = ~ (Dj'exp(-[CL//Vd][tci-tDj- PT])) 
/=1 
× (1 - e x p ( -  [CL/Vd][PT])) 
(CL)(PT) 
r 
Cvi= ~_, [(Dj'exp(-[CL/Vd][tci-tn/-PT]) 
j = l  
× ( ( t c i -  tog)(1 - exp(- [ C L / V d ] [ P T ] ) )  
ccLi = ~ [ Dj'exp(-[CL/Vd][tci- to/- PT]) 
j = l  
×((CL(to/ - tc i ) -Vd)  
× (1 - e x p ( -  [CL/Vd][PT])) + CL. PT) 
/(CL 2" Vd" PT)] 
It should be noted that PT is a parameter which is 
not estimated by the program, but is assigned by 
the user. 
The value of PT is assumed to be the same for 
all the doses that have been administered to the 
patient. Furthermore, as shown by the above equa- 
tions, the program is unable to process concentra- 
tion data which have been measured during the 
time period over which the zero-order absorption 
occurs. Thus, in the case of oral administrations, 
concentration values measured after a dose but 
before the subsequent peak must not be used for 
the Bayesian feedback; similarly, in the case of the 
constant-rate intravenous administrations, con- 
centration values measured during an infusion 
cannot be processed. Thus, care should be taken in 
recommending sampling times for peak levels after 
oral dosing of a drug. 
APPENDIX 2: USER INSTRUCTIONS FOR 
OPERATING TH E PROGRAM 
General information 
The program can be run on a Hewlett-Packard 
HP-41CV calculator equipped with an 'extended 
TABLE 4 












M D  
R N D  




Peak time, i.e. the period over which the zero- 
order absorption occurs. 
Time at which a dose has been given or a 
plasma level has been measured. All time val- 
ues must  be entered as date and hour: the day 
on which the first dose was given is arbitrarily 
denominated as 'day 1'; the code for all subse- 
quent days is defined accordingly. 
Day code (see 'H') .  
Dose. 
Plasma drug concentration. 
Apparent  volume of distribution. 
Clearance. 
Half-life. 
Desired peak plasma concentration at steady 
state. 




Amount  by which the calculated values of LD 
and M D  are rounded. 
Dosing interval. 
Predicted peak plasma concentration at steady 
state. 
Predicted trough plasma concentration at 
steady state. 
Sum of squared residuals between experimen- 
tal and fitted values of concentration. 
a The population parameters are denoted by the following 
symbols: CV RE, coefficient of variation for the intraindivid- 
ual and model misspecification variability error; M E AN Vd, 
mean value of the apparent  volume of distribution; SDEV 
Vd, standard deviation of the apparent volume of distribu- 
tion; MEAN CL, mean value of the clearance; SDEV CL, 
standard deviation of the clearance. 
functions module' (HP 82180A) and an 'extended 
memory' module (HP 82181A). The use of a printer 
is optional. The program is split into three subpro- 
grams called: program BAYES, program LS, and 
program DOSE. These three subprograms must be 
loaded into the 'extended memory' of the calcula- 
tor. This extended memory is a continuous one 
and loading operations must therefore be per- 
formed once only. The program can be stored on 
11 magnetic cards. The typical running time for 
the program is approximately 5 min. 
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Program listings 
Listing for programs BAYES, LS and DOSE 
are available from the authors on request. 
Initialization of the program 
Before using the program, the user must clear 
the whole main program memory of the calculator. 
Moreover, if 'assignments' to keys 'A', 'shift A', 
'B', 'C', 'D', 'E', 'shift E', 'F', 'G', 'H', 'I' or 'J' 
have been done previously, these assignments must 
be cleared. 
User instructions 
All symbols used are given in Table 4. User 
instructions for operating the program are re- 
ported in Table 5. These instructions are intended 
for use with a printer attached to the calculator. 
However, the program can also be used without a 
printer. Under this circumstance, the user instruc- 
tions are slightly different. A copy of these instruc- 
tions can be requested from the authors. 
Note. As previously stated, individualized calcu- 
lation of the dosage capable of eliciting the desired 
peak and trough levels is obtained by using the 
equations described by Ng [29]. Through these 
equations, the program determines the dosage regi- 
men (maintenance dose and dosing interval) that 
is likely to produce the desired peak and trough 
levels at steady state. In detail, the program first 
performs exact calculation of the dosage regimen 
(maintenance dose and dosing interval) that pro- 
duces the desired peak and trough levels. The 
calculated values of both the maintenance dose 
and dosing interval are then rounded for practical 
purposes. Finally, the peak and trough steady-state 
levels that result from the 'practical' dosage regi- 
men are predicted. 
Furthermore, a loading dose is also calculated 
by the program. The loading dose is the dose that 
is capable of producing the desired peak and trough 
levels after the first administration. The latter 
function of the program provides, however, little 
clinical utility because the calculated loading dose 
is appropriate only if enough time has elapsed 
since the last dose for the plasma level to approach 
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TABLE 5 
User instructions a 
Step Display Procedure Enter Press 
1 Initialize 'shift  a' b 
2 INST. ABSOR.? Answer 1 (YES = instantaneous 1 or 0 ' R / S '  
YES = 1 NO = 0 absorption) or 0 (NO = 
zero-order absorption) 
3 PEAK TIME = ? Enter PT (only when the zero-order PT ' R / S '  
absorption is selected) 






















NEW POP ESTIM? 
YES = 1 NO = 0 
BAY = 1 LS = 2? 
PEAK TIME = ? 
DES. MAX = ? 
DES. MIN = ? 
R N D  = ? 
NEW PRED? 
YES = 1 NO = 0 
END 
Enter D C O D E  (only if a new D C O D E  
day is selected) 
Enter H H 
Enter D D 
Repeat steps 5a - 5b- 5c for all subsequent doses c 
Enter D C O D E  (only if a new D C O D E  
day is selected) 
Enter H H 
Enter C C 
Repeat steps 7a - 7b - 7c for all subsequent plasma levels c 
Correct input errors, if any a 
Press ' F'  
Answer I ( = YES) to enter popula- 1 or 0 
tion estimates different from 
those stored in the program memory; 
answer 0 ( = NO) if the population 
estimates must  not  be changed. 
The population estimates are 
printed e 
The program calculates the Bayesian 
estimates for Vd, CL, and T 1 / 2  and 
then the least-squares estimates 
for the three parameters and the 
S W S R  value. The results are printed 
Start computat ion of dosage regimens 
Answer 1 ( = BAY) to select Bayesian 1 or 2 
prediction of dosage; 
answer 2 ( = LS) to select least- 
squares prediction 
Enter PT. This parameter must  PT 
always be input. Select a short 
PT value when the model with 




Enter R N D  
The dosage regimen is 
calculated and printed 
Answer 1 ( = YES) to start a 1 or 0 
new dosage prediction; 
otherwise, answer 0 ( = NO) 
This message is printed after 
the final dosage prediction 
DES. MAX 
DES. MIN 
R N D  
'A '  b 
'B '  b 
'C '  b 
'A '  b 
'D '  b 
'E '  b 
'F '  b 
' R / S '  
, j ,  b 
' R / S '  
' R / S '  
' R / S '  
' R / S '  
' R / S '  
' R / S '  
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zero. As a result, the calculated loading dose should 
be administered only if at least five patient's Fac- 
tor VIII half-lives have elapsed since administra- 
tion of the last dose; otherwise, the calculated 
loading dose will initially elicit plasma concentra- 
tions exceeding the desired values. 
APPENDIX 3: USE OF THE HP-41 PROGRAM 
FOR ESTIMATING POPULATION KINETIC 
P A R A M E T E R S  A C C O R D I N G  TO T H E  
STANDARD TWO-STAGE METHOD 
Two methods are commonly used for estimat- 
ing population pharmacokinetic parameters: the 
NONMEM method [31] and the Standard Two- 
Stage (STS) method [28,32]. 
The STS method has been shown to be less 
precise and less accurate than NONMEM in 
estimating population kinetic parameters fore 
routine pharmacokinetic data [28]. This is particu- 
larly apparent when routine data characterized by 
few data points per individual are to be analyzed. 
The STS method is, however, useful in situations 
where there is much data per individual. As pointed 
out by Sheiner [28], it can work fairly well in these 
situations. 
Briefly, the STS method requires that each indi- 
vidual's data be fitted separately to the kinetic 
model (first stage) and that the individual parame- 
ter estimates be combined to yield the population 
parameters (second stage). 
First stage 
Three kinetic parameters (CL i, Vd i and the 
sum of weighted squared residuals) must be calcu- 
lated from each individual's data by weighted non- 
linear least-squares regression analysis. Our HP-41 
program can be used for this purpose because the 
weighted least-squares subroutine allows the above 
parameters to be estimated. In our program, the 
concentration data are weighted according to the 
squared reciprocal of the measured concentrations 
(weight = 1/C2);  as a result, the fitting procedure 
yields a sum of weighted squared residuals 
(SWSR), which is a dimensionless quantity. 
Second stage 
The individual values of CLi, Vdi, and S WSR, 
are combined so as to yield the population param- 
eters CLpo p, Vpop, SDcL , SD v and CVRE. 
The population parameters are estimated as 
follows: CLpo p and Vpo p are determined as the 
arithmetic averages of the individual CL~ and Vd~ 
values, respectively, while SDcL and SD v are 
estimated from the standard deviations of the val- 
ues of CL~ and Vd~. CVRE is calculated from the 
following equation [28]: 
v / ~  S W S R  i 
CVRE = (Npair  s -  2 N )  
where Npair s is the total number of time-concentra- 
tion data pairs over all individuals and N is the 
number of individuals. CVRE is a dimensionless 
quantity. 
TABLE 5 (continued) 
a The 'size' of  the program is 137. This number  of registers is allocated to data storage automatically. Before using the program, the 
BAYES subprogram must  be loaded from extended memory into main memory. This loading operation must  not be performed if 
program BAYES is already present in main memory. No  other program must  be present in main memory. 
b The key must  be pressed with the calculator in User mode. 
c The number  of measured plasma levels and the number  of administered doses must  be less than 25. 
a The procedure to correct an erroneous input is as follows: a Table with the identification codes for the storage registers containing 
the values of  Dj, tDj, C i and tci must  first be examined (this Table is available from the authors on request). The key 'shif t  E' must  
then be pressed in User mode; the calculator asks (REG?) the code for the register containing the erroneous input; such a code must  
be entered, followed by the key ' R / S ' .  Finally the calculator asks (NEW VALUE?) the correct value and such a value must  be 
entered followed by the key ' R / S ' .  
e To use population estimates other than those stored in program memory,  the procedure is as follows: after each input request of the 
calculator, the appropriate population parameter  must  be entered followed by the ' R / S '  key. 
